BioSyent Inc.

BioSyent Inc.

BIOYF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$138.66M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BioSyent Inc.BioSyent Inc.20.21.21%22%2.40.1
$11.94

Current Fair Value

1.9% downside

Overvalued by 1.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$138.66 Million
Enterprise Value$131.49 Million
Annual dividend$0.16
Dividend yield1.21%
Earnings per Share$0.8
Beta0.63
Outstanding Shares11,393,271

Return

Return on Equity21.58%ROE
Return on Assets15.47%
Return on Invested Capital29.38%

Valuation & Multiples

P/E Ratio20.22P/E Ratio
PEG304.43PEG
Price to Sales2.43Price to Sales
Price to Book Ratio3.04Price to Book Ratio
Enterprise Value to Revenue2.07
Enterprise Value to EBIT9.49
Enterprise Value to Net Income13
Total Debt to Enterprise0.03
Debt to Equity0.07Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 19, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$13.69 M
Consensus analyst estimate

Next Earnings Call

Expected Date
March 17, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$13.87 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About BioSyent Inc.

711 employees
CEO: René C. Goehrum

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iro...

Questions & Answers